Exelixis Inc Impairment of Long-Lived Assets Held-for-use
Exelixis Inc (EXEL) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-02-10
- Exelixis Inc impairment of long-lived assets held-for-use for the quarter ending 2026-01-02 was $0.00.
- Exelixis Inc impairment of long-lived assets held-for-use for the quarter ending 2025-10-03 was $0.00, a 100.00% decline year-over-year.
- Exelixis Inc impairment of long-lived assets held-for-use for the quarter ending 2025-01-03 was $0.00.
- Exelixis Inc impairment of long-lived assets held-for-use for the quarter ending 2024-09-27 was $51.67M.
- Exelixis Inc impairment of long-lived assets held-for-use for fiscal 2026 was $0.00, a 100.00% decline from fiscal 2025.
- Exelixis Inc impairment of long-lived assets held-for-use for fiscal 2025 was $51.67M.
- Exelixis Inc impairment of long-lived assets held-for-use for fiscal 2023 was $0.00.
- Exelixis Inc impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2026-01-02 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $0.00 derived: sum of 2 quarters · filed 2026-02-10 | $0.00 10-K · filed 2026-02-10 | |
| 2025-10-03 | $0.00 10-Q · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | ||
| 2025-01-03 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $51.67M derived: sum of 2 quarters · filed 2026-02-10 | $51.67M 10-K · filed 2026-02-10 | |
| 2024-09-27 | $51.67M 10-Q · filed 2025-11-04 | $51.67M 10-Q · filed 2025-11-04 | ||
| 2023-12-29 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $0.00 derived: sum of 2 quarters · filed 2026-02-10 | $0.00 10-K · filed 2026-02-10 | |
| 2023-09-29 | $0.00 10-Q · filed 2024-10-29 | $0.00 10-Q · filed 2024-10-29 | ||
| 2022-12-30 | $0.00 10-K · filed 2025-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |